There are 150 resources available
Checkpoint Inhibition in Esophageal Cancer
Presenter: Yelena Janjigian, United States
Session: Session VIII: Esophageal and Gastric Cancers
Resources:
Slides
Checkpoint Inhibition in Gastric Cancer
Presenter: Kei Muro, Japan
Session: Session VIII: Esophageal and Gastric Cancers
Resources:
Slides
New Targets and Agents in Upper GI Cancer
Presenter: Florian Lordick, Germany
Session: Session VIII: Esophageal and Gastric Cancers
Resources:
Slides
Endoscopic Management of Early Esophageal and Gastric Cancer
Presenter: Raf Bisschops, Belgium
Session: Session VIII: Esophageal and Gastric Cancers
Resources:
Slides
Pathogenesis and Subtypes of HCC
Presenter: Josep Llovet, Spain
Session: Session IX: Hepatocellular Cancer
Resources:
Slides
Diagnostic and Imaging Challenges in HCC
Presenter: Vincent Vandecaveye, Belgium
Session: Session IX: Hepatocellular Cancer
Resources:
Slides
Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the Phase 3 HIMALAYA study
Presenter: Arndt Vogel, Germany
Session: Session IX: Hepatocellular Cancer
Resources:
Slides
Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients with advanced hepatocellular carcinoma (aHCC): 5-year results from CheckMate 040
Presenter: Ignacio Melero, Spain
Session: Session IX: Hepatocellular Cancer
Resources:
Slides
SO-13: Pembrolizumab in patients with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: updated data from the open-label, phase 2 KEYNOTE-224 study
Presenter: Arndt Vogel, Germany
Session: Session IX: Hepatocellular Cancer
Resources:
Slides
SO-14: Atezolizumab Plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: An international study
Presenter: Andrea Casadei-Gardini, Italy
Session: Session IX: Hepatocellular Cancer
Resources:
Slides